IL308071A - Process for preparing NLRP3 inhibitors - Google Patents

Process for preparing NLRP3 inhibitors

Info

Publication number
IL308071A
IL308071A IL308071A IL30807123A IL308071A IL 308071 A IL308071 A IL 308071A IL 308071 A IL308071 A IL 308071A IL 30807123 A IL30807123 A IL 30807123A IL 308071 A IL308071 A IL 308071A
Authority
IL
Israel
Prior art keywords
preparation
nlrp3 inhibitors
nlrp3
inhibitors
Prior art date
Application number
IL308071A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL308071A publication Critical patent/IL308071A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/40Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL308071A 2021-06-23 2022-06-23 Process for preparing NLRP3 inhibitors IL308071A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202141028180 2021-06-23
PCT/EP2022/067126 WO2022268935A2 (en) 2021-06-23 2022-06-23 Novel process

Publications (1)

Publication Number Publication Date
IL308071A true IL308071A (en) 2023-12-01

Family

ID=82458485

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308071A IL308071A (en) 2021-06-23 2022-06-23 Process for preparing NLRP3 inhibitors

Country Status (12)

Country Link
US (1) US20240150291A1 (https=)
EP (1) EP4359385A2 (https=)
JP (1) JP2024524215A (https=)
KR (1) KR20240024842A (https=)
CN (1) CN118019727A (https=)
AR (1) AR126215A1 (https=)
AU (1) AU2022300325A1 (https=)
CA (1) CA3219597A1 (https=)
IL (1) IL308071A (https=)
MX (1) MX2023014547A (https=)
TW (1) TW202317514A (https=)
WO (1) WO2022268935A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR128498A1 (es) * 2022-02-15 2024-05-15 Hoffmann La Roche Procesos novedosos
WO2024133610A1 (en) * 2022-12-23 2024-06-27 F. Hoffmann-La Roche Ag Proccesses for the preparation of an nlrp3 inhibitor
IL325043A (en) 2023-08-16 2026-01-01 Hoffmann La Roche Process for the preparation of 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indecen-4-yl)carbamoyl)piperidine-4-sulfonamide
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69727837T2 (de) * 1997-05-02 2004-12-30 Dr. Reddy's Research Foundation, Hyderabad Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel
HUP0303204A3 (en) * 2000-11-16 2010-04-28 Sankyo Co 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
WO2002100833A1 (en) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
US7220735B2 (en) * 2002-04-18 2007-05-22 Schering Corporation Benzimidazolone histamine H3 antagonists
TW200524865A (en) * 2003-10-08 2005-08-01 Nicholas Piramal India Ltd Fibrinogen receptor antagonists and their use
DOP2006000009A (es) * 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
JP5508027B2 (ja) * 2007-02-22 2014-05-28 メルク セローノ ソシエテ アノニム キノキサリン化合物及びその使用
JP5898962B2 (ja) * 2012-01-11 2016-04-06 東京応化工業株式会社 レジスト組成物及びレジストパターン形成方法
WO2017095758A1 (en) * 2015-12-01 2017-06-08 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver x receptor beta agonists, compositions, and their use
US11465992B2 (en) * 2017-07-07 2022-10-11 Inflazome Limited Sulfonamide carboxamide compounds
GB201712282D0 (en) * 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
EP3668861A1 (en) * 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3773576A4 (en) * 2018-03-26 2021-12-29 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
CR20200588A (es) * 2018-05-04 2021-06-24 Inflazome Ltd Compuestos novedosos
CA3113573A1 (en) * 2018-09-21 2020-03-26 Novartis Ag Isoxazole carboxamide compounds and uses thereof
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
GB201819083D0 (en) * 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
WO2020157069A1 (en) * 2019-01-28 2020-08-06 NodThera Limited Amino heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
WO2022268935A3 (en) 2023-02-02
TW202317514A (zh) 2023-05-01
EP4359385A2 (en) 2024-05-01
US20240150291A1 (en) 2024-05-09
CN118019727A (zh) 2024-05-10
AR126215A1 (es) 2023-09-27
KR20240024842A (ko) 2024-02-26
AU2022300325A8 (en) 2023-11-16
AU2022300325A1 (en) 2023-11-02
WO2022268935A2 (en) 2022-12-29
CA3219597A1 (en) 2022-12-29
JP2024524215A (ja) 2024-07-05
MX2023014547A (es) 2024-04-29

Similar Documents

Publication Publication Date Title
IL308071A (en) Process for preparing NLRP3 inhibitors
IL287042A (en) Inflammatory inhibitors of nlrp3
PL4337652T3 (pl) Inhibitory NLRP3
IL280336A (en) NLRP3 inflammasome inhibitors
SI4363406T1 (sl) Zaviralci inflamasoma nlrp3
EP3982949A4 (en) MRSA1 INHIBITORS
IL306022A (en) NLRP3 inflammasome inhibitors
IL289453B2 (en) Process for preparing ridinilazole and its crystalline forms
ZA201803942B (en) Novel processes for preparation of integrase inhibitor
IL289904A (en) A process for preparing biphenylamines
HUE067878T2 (hu) Eljárás alkilamidotiazolok gyártásához
IL290181B2 (en) Process for preparing fluonesulfone
HUP2300098A1 (hu) Eljárás upadacitinib elõállítására
PT4337652T (pt) Inibidores do nlrp3
IL280312A (en) Process for preparing bromodomain inhibitors
IL307678A (en) Methods of administering certain VMAT2 inhibitors
IL287941B (en) A method for making kraselam
IL321066A (en) Processes for preparing NLRP3 inhibitor
KR102623532B9 (ko) 납-금속 화합물 단결정의 개질방법
IL326079A (en) Process for preparing beta-hydroxyketones
IL325770A (en) Process for preparing thiophenones
HK40109676A (en) Inhibitors of nlrp3
CA3274804A1 (en) Proccesses for the preparation of an nlrp3 inhibitor
IL314924A (en) Processes for the preparation of phenyltetrahydrofuran compounds
IL311430A (en) Process for the preparation of safinamide